A multicenter, retrospective study to compare chemotherapy (HyperCVAD, MOAD, Larson/CALGB-9511) to novel agents (blinatumomab or inotuzumab) as first salvage therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Latest Information Update: 30 Aug 2022
At a glance
- Drugs Blinatumomab (Primary) ; Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Pegaspargase; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 30 Aug 2022 New trial record
- 01 Aug 2022 Primary endpoint has not been met (Overall survival (OS)) , according to Results published in the Leukemia and Lymphoma
- 01 Aug 2022 Results published in the Leukemia and Lymphoma